Pfizer earnings miss puts pharma pipeline focus front and center Pfizer’s earnings miss is fueling debate far beyond one quarter, with investors zeroing in on pipeline strength, future growth, and what comes next for the pharma giant. /blog/pfizer-earnings-miss-pharma-pipeline-focus